Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Knight Therapeutics Inc T.GUD

Alternate Symbol(s):  KHTRF

Knight Therapeutics Inc. is a Canada-based specialty pharmaceutical company. The Company's principal business activity includes developing, acquiring, in-licensing, out-licensing, manufacturing, marketing and distributing pharmaceutical products in Canada, Latin America and select international markets. It finances other life sciences companies and secures product distribution rights for Canada and select international markets. The Company invested in life sciences venture capital funds whereby the Company may receive preferential access to healthcare products for Canada and select international markets. It develops pharmaceutical products, including those to treat neglected tropical and rare pediatric diseases. The Company's portfolio consists of pharmaceutical products with molecules and includes both in-licensed products, such as Lenvima, Cresemba, Halaven, Trelstar, Akynzeo, Ambisome as well as products owned (or partially owned) by it, such as Exelon and Impavido.


TSX:GUD - Post by User

Comment by Snowballgrowthon Aug 19, 2020 3:47pm
66 Views
Post# 31430335

RE:RE:EPS 2020-2021

RE:RE:EPS 2020-2021
wagyusteak wrote:
Snowballgrowth wrote: We know that over long term only the EPS will drive the stock price much higher. I saw an analyst has a 0.33 $ EPS forecast for 2021. Do you think it is realistic ?


I would focus on the free cash flows. EPS are wildly affected by financial assets. FCF will give us a better picture. Assuming they can reorganize GBT to become a better and leaner organization and they can find some revenue synergies, they could make $100mil FCF in 5 years. if the stock price remains flat until that, the market cap will be about $800-$900mil (assum they bought back another 10%). That's 8x-9x FCF ~ 12.5% - 11% FCF yield, pretty cheap, given that the interest rate is almost 0%. So, the only way for the yield to go down is the stock price has to go up. Anyway, my expectation is either we make our money through special dividend+share buyback(if the stock price remains flat) or the stock price will go up to drive down the FCF yield.


Good input, I like the numbers :)

Like GUD, the analyst uses "earning ajusted" so likely very close to FCF, right ?

$ 100 M FCF in 5 years could be fantastic

Other acquisitions could add to the optimistics scenario

<< Previous
Bullboard Posts
Next >>